Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606411 · ClinicalTrials.gov registry record · Early Phase 1
Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder
A Early Phase 1 study of Sleep-Related Eating Disorder, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT00606411: Completed Early Phase 1 study of Sleep-Related Eating Disorder, sponsored by Massachusetts General Hospital.
NCT00606411 is a Early Phase 1 study of Sleep-Related Eating Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 34 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00606411, a Early Phase 1 study of Sleep-Related Eating Disorder, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to learn about the safety and effectiveness of oral (taken by mouth) topiramate in treating Sleep-Related Eating Disorder (SRED).
Primary Outcome
Frequency of sleep-related eating episodes was measured as the number of nights a participant had an episode within the previous two weeks. The change was measured by comparing the last study visit (by the participant) from to the baseline results.
Conditions Studied
Interventions
- DRUG Topiramate or Placebo
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-01 |
| Est. Completion | 2018-11-29 |
| Phase | Early Phase 1 |
What the finished NCT00606411 record still lists
NCT00606411 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Sleep-Related Eating Disorder appearing as the primary indexed condition, and to 1 intervention - of which Topiramate or Placebo is the first listed.
NCT00606411 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00606411 about?
NCT00606411 is a clinical study titled "Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder". The purpose of the study is to learn about the safety and effectiveness of oral (taken by mouth) topiramate in treating Sleep-Related Eating Disorder (SRED).
What is the current status of trial NCT00606411?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 34 participants. The study started on 2008-01. Estimated completion is 2018-11-29.
What conditions does trial NCT00606411 study?
This clinical trial studies the following conditions: Sleep-Related Eating Disorder.
What interventions are being tested in trial NCT00606411?
The interventions under investigation include: Topiramate or Placebo (DRUG).
Who is sponsoring clinical trial NCT00606411?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00606411 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00606411's enrollment target sits among peer trials
34 748th of 2000 higher than 1,239 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia